Search results for "Number needed to treat"

showing 10 items of 18 documents

Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublis…

2018

Zofenopril is a lipophilic, sulfhydryl group-containing angiotensin-converting enzyme (ACE)-inhibitor, characterized by wide tissue distribution, long duration of action, and pleiotropic effects on endothelial dysfunction. Its clinical efficacy and safety have been described in the four randomized controlled trials of the SMILE program, which globally enrolled more than 3600 patients in post-acute myocardial infarction (AMI) setting. The SMILE-4 study specifically selected patients with left ventricular dysfunction at admission, and compared the effects of zofenopril or ramipril in combination with acetylsalicylic acid (ASA). Zofenopril demonstrated its superiority over ramipril in reducing…

0301 basic medicineRamiprilmedicine.medical_specialtyCaptoprilPopulationMyocardial InfarctionCardiologyAngiotensin-Converting Enzyme InhibitorsHeart failureReviewAcute myocardial infarction030204 cardiovascular system & hematologylaw.inventionZofenopril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineAcute myocardial infarction; Angiotensin-converting enzyme inhibitors; Cardiology; Heart failure; Left ventricular dysfunction; Ramipril; Zofenopril; Pharmacology (medical)MedicineHumansPharmacology (medical)Myocardial infarctioneducationRandomized Controlled Trials as Topiceducation.field_of_studyLeft ventricular dysfunctionEjection fractionbusiness.industryGeneral Medicinemedicine.diseaseZofenopril030104 developmental biologyTreatment OutcomechemistryAngiotensin-converting enzyme inhibitorHeart failureCardiologyNumber needed to treatbusinessmedicine.drug
researchProduct

Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER…

2021

Abstract Aims In this secondary analysis of the VOYAGER trial, rivaroxaban 2.5 mg twice/day plus aspirin 100 mg/day was assessed in older adults. Advanced age is associated with elevated bleeding risk and unfavourable net benefit for dual antiplatelet therapy in chronic coronary artery disease. The risk–benefit of low-dose rivaroxaban in patients ≥75 years with peripheral artery disease (PAD) after lower extremity revascularization (LER) has not been described. Methods and results The primary endpoint was a composite of acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke, or cardiovascular death. The principal safety outcome was thrombolysis in myocardial infarct…

Acute limb ischaemiamedicine.medical_specialtyBrain IschemiaPeripheral Arterial DiseaseRivaroxabanInternal medicineClinical endpointHumansMedicineMyocardial infarctionAgedRivaroxabanAspirinbusiness.industryAbsolute risk reductionNumber needed to harmmedicine.diseaseStrokeCardiologyNumber needed to treatDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsTIMIFactor Xa Inhibitorsmedicine.drugEuropean Heart Journal
researchProduct

Improving the Course of Depressive Symptoms After Inpatient Psychotherapy Using Adjunct Web-Based Self-Help: Follow-Up Results of a Randomized Contro…

2019

Background We recently showed in a randomized controlled trial that Web-based self-help as an adjunct improved the effectiveness of multimodal inpatient psychotherapy for depression. Objective The aims of this study were (1) to determine whether a Web-based self-help adjunctive to multimodal inpatient psychotherapeutic treatment could also improve the course of depressive symptoms and (2) to identify predictors of residual depressive symptoms at follow-up. Methods Overall, 229 patients were randomized either to the Web-based self-help intervention group (Deprexis) or an active control group (Web-based information about depression and depressive symptoms) in addition to multimodal inpatient…

AdultMalemedicine.medical_specialtyAdolescent020205 medical informaticsMEDLINEPsychological interventionHealth Informatics02 engineering and technologylaw.inventionYoung Adult03 medical and health sciences0302 clinical medicineQuality of lifeRandomized controlled triallaw0202 electrical engineering electronic engineering information engineeringHumansMedicineDepression (differential diagnoses)AgedOriginal PaperInpatientsInternetDepressionbusiness.industrypsychology clinicalMiddle AgedCombined Modality TherapyMental health030227 psychiatryPsychotherapySelf-Help GroupsQuality of LifeNumber needed to treatPhysical therapyAnxietyFemalemedicine.symptombusinessmental healthaftercareFollow-Up StudiesJournal of Medical Internet Research
researchProduct

III: „Relatives Risiko” und „NNT” - anschauliche Maße für binäre Daten

2002

Description of categorial data can often be based on contingency tables. However, percentages appearing in such tables must be meaningful: For most applications, it may be useful to employ factors of causal influence as the row entry variable and relate percentages to sub-groups defined by these row entries ("row percentages"). The comparison of success frequencies (i. e. binary information on "therapy success yes/no") may be based on two therapies, respective success frequencies and their ratio, the relative risk. In addition the success frequencies' difference, the absolute (or excess) risk, can be transformed into the "number needed to treat" (NNT). Many international journals demand thi…

Contingency tableOphthalmologyVariable (computer science)Relative valuebusiness.industryRelative riskBinary dataStatisticsNumber needed to treatMedicineRisk factorbusinessNumero signKlinische Monatsblätter für Augenheilkunde
researchProduct

Treatment options in HBV.

2005

The available evidence on interferon-alpha (IFN) treatment for chronic hepatitis B is sufficient to conclude that in patients with HBeAg positive chronic hepatitis, standard IFN therapy significantly improves clearance of HBeAg (number needed to treat [NNT] = 4), loss of HBV-DNA (NNT = 4) and clearance of HBsAg (NNT = 18). HBeAg positive patients with normal or slightly raised ALT should be treated only if there is histological evidence of progressive disease. In patients with HBeAg negative chronic hepatitis, less than 20% of subjects who have achieved an end-of-treatment virological response after a course of standard IFN maintain a sustained virological response in the long-term. IFN tre…

Hepatitis B virusHBsAgmedicine.medical_specialtyAdefovirmedicine.disease_causeAntiviral AgentsGastroenterologyHepatitis B AntigensLiver diseaseInternal medicineAdefovirHumansMedicineHepatitis B virusHepatologybusiness.industryvirus diseasesLamivudineHIVHepatitis Bmedicine.diseaseHepatitis Bdigestive system diseasesTreatmentTreatment OutcomeHBeAgLamivudineDNA ViralImmunologyNumber needed to treatInterferonbusinessLiver diseasemedicine.drug
researchProduct

Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019

2019

Resumen Un grupo de expertos convocado por la Sociedad Espanola de Arteriosclerosis (SEA) se ha encargado de actualizar el documento de la SEA sobre las indicaciones de los inhibidores de PCSK9 (iPCSK9) en la practica clinica publicadas en 2016. Esta actualizacion es necesaria porque en el periodo transcurrido hasta la actualidad se han publicado los resultados de los ensayos clinicos realizados a gran escala con iPCSK9 que demuestran que, ademas de su alta potencia para disminuir el colesterol aterogenico, disminuyen el riesgo de presentar episodios de enfermedad cardiovascular aterosclerotica en los pacientes con enfermedad tanto estable como reciente, y con un alto grado de seguridad. La…

Inhibidores de la proproteína convertasa subtilisina kexina 9ArteriosclerosisEnfermedad cardiovascularFamilial hypercholesterolemiaClinical indicationsLow density lipoprotein030204 cardiovascular system & hematologyArteriosclerosi03 medical and health sciencesLipoproteínas de baja densidad0302 clinical medicineIndicaciones clínicasTratamientoPharmacology (medical)030212 general & internal medicineConsensus documentHipercolesterolemia familiarNumber needed to treatCardiovascular diseaseDocumento de consensoTreatmentArterioesclerosiCholesterolProprotein convertase subtilisin kexin 9 inhibitorsCardiology and Cardiovascular MedicineColesterolNúmero necesario a tratar
researchProduct

A Multicomponent Exercise Intervention that Reverses Frailty and Improves Cognition, Emotion, and Social Networking in the Community-Dwelling Frail E…

2016

Abstract Background Frailty can be an important clinical target to reduce rates of disability. Objective To ascertain if a supervised-facility multicomponent exercise program (MEP) when performed by frail older persons can reverse frailty and improve functionality; cognitive, emotional, and social networking; as well as biological biomarkers of frailty, when compared with a controlled population that received no training. Design This is an interventional, controlled, simple randomized study. Researchers responsible for data gathering were blinded for this study. Setting Participants from 2 primary rural care centers (Sollana and Carcaixent) of the same health department in Spain were enroll…

MaleAgingmedicine.medical_specialtyFrail ElderlyEmotionsPopulationPsychological interventionPoison controlSocial Networkinglaw.invention03 medical and health sciencesSocial supportCognition0302 clinical medicinePhysical medicine and rehabilitationRandomized controlled triallawmedicineHumans030212 general & internal medicineeducationGeneral NursingAgededucation.field_of_studybusiness.industryHealth PolicyTinetti testGeneral MedicineExercise TherapyPhysical therapyNumber needed to treatFemaleGeriatric Depression ScaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryJournal of the American Medical Directors Association
researchProduct

Estimating adjusted NNT measures in logistic regression analysis

2007

The number needed to treat (NNT) is a popular measure to describe the absolute effect of a new treatment compared with a standard treatment or placebo in clinical trials with binary outcome. For use of NNT measures in epidemiology to compare exposed and unexposed subjects, the terms 'number needed to be exposed' (NNE) and 'exposure impact number' (EIN) have been proposed. Additionally, in the framework of logistic regression a method was derived to perform point and interval estimation of NNT measures with adjustment for confounding by using the adjusted odds ratio (OR approach). In this paper, a new method is proposed which is based upon the average risk difference over the observed confou…

MaleStatistics and ProbabilityBiometryEpidemiologyInterval estimationCoverage probabilityCoronary DiseaseLogistic regressionCohort StudiesBiasRisk FactorsStatisticsConfidence IntervalsOdds RatioHumansMedicineClinical Trials as Topicbusiness.industrySmokingConfoundingConfounding Factors EpidemiologicOdds ratioConfidence intervalLogistic ModelsNumber needed to treatbusinessCohort studyStatistics in Medicine
researchProduct

Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol \textless70 mg/dL During 5 Years After Ischemic Stroke

2020

Background and Purpose— The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature or aortic arch plaque >4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results …

Malemedicine.medical_specialtyStatinTime Factorsmedicine.drug_class[SDV]Life Sciences [q-bio]Brain IschemiaLDLchemistry.chemical_compoundDrug Delivery SystemsEzetimibeInternal medicinemedicineClinical endpointHumansangiographyMyocardial infarctionStrokeAgedAdvanced and Specialized NursingCerebral infarctionCholesterolbusiness.industryAnticholesteremic Agentsinformed consentcholesterolCholesterol LDLMiddle Agedmedicine.diseaseEzetimibestroke[SDV] Life Sciences [q-bio]aortachemistryNumber needed to treatCardiologyFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Numbers Needed to Treat with Posaconazole Prophylaxis to Prevent Invasive Fungal Infection and Death

2008

Microbiology (medical)medicine.medical_specialtyPosaconazoleInfectious Diseasesbusiness.industrymedicineNumber needed to treatbusinessIntensive care medicineSurgerymedicine.drugClinical Infectious Diseases
researchProduct